Yesterday, the Federal Circuit issued an opinion clarifying that the introduction of
new evidence is not only permitted, but "is to be
expected," in inter partes review proceedings.
As long as the opposing party is given notice of the evidence and
an opportunity to respond to it, the introduction of new evidence
is permissible under the Administrative Procedure Act (APA).
As background, the patents challenged in the IPRs on appeal
relate to treating Pompe's disease with injections of a human
acid α-glucosidase. The PTAB instituted IPR on various
obviousness grounds. After institution, the patent owner
argued that, because of all of the combinations of references
described in in vivo experiments, a person of ordinary
skill in the art would not find those experiments predictive of
results in a human patient. The patent owner further argued
that because the PTAB did not institute review based on any
references that included in vivo data, the petitioner
should not be